Merck easily beat Wall Street expectations despite first-quarter profit plunging 44 percent. The company was hurt by the sale of its consumer health business, unfavorable currency exchange rates and competition to some drugs.
Kenneth C. Frazier, chairman and CEO of Merck & Co., Inc., was elected chairman of the Board...
Merck is introducing Clinical Diabetes management for more than 5000 medical students in 18...
Arvinas announced a strategic collaboration with Merck with the goal of creating novel therapeutics based on protein degradation.
Merck & Co. says its board approved the repurchase of up to $10 billion more of its stock. The company said that amount will be added to the $1.7B remaining available for repurchase under a prior authorization.
Lycera Corp. today announced the achievement of a milestone under the Company's collaboration agreement with Merck, known as MSD outside the United States and Canada, triggering an undisclosed payment.
The company said Friday that the Food and Drug Administration has canceled a March 18 meeting to review sugammadex, which is designed to help patients "wake up" after surgical anesthesia.
For years scientists at Canada's National Microbiology Laboratory struggled to figure out how to test whether a vaccine developed at the Winnipeg lab would prevent people from contracting Ebola. Now, finally, three studies in West Africa may provide that answer.
Eisai and Merck have announced a clinical trial collaboration to evaluate the safety, tolerability and efficacy of Merck’s anti-PD-1 therapy, pembrolizumab, in combination with Eisai oncology compounds lenvatinib mesylate and eribulin mesylate.
GARDASIL®9 Recommended by CDC’s Advisory Committee on Immunization Practices for Females Aged 9-26 and Males Aged 9-21February 26, 2015 3:33 pm | News | Comments
Merck has announced that the CDC’s Advisory Committee on Immunization Practices (ACIP) voted to include GARDASIL® 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) in the recommendations for use of HPV vaccines.
Merck has granted a free license allowing one of its HIV medicines to be made and sold inexpensively for use in young children in poor countries hard hit by the AIDS virus.
NGM Biopharmaceuticals, Inc., a privately-held biotechnology company and Merck announced they have entered into a multi-year collaboration to research, discover, develop and commercialize novel biologic therapies across a wide range of therapeutic areas.
Zachary Zwerko pleaded guilty in Manhattan federal court to conspiring to commit securities fraud and three securities fraud counts. A plea agreement recommended a three to four-year prison sentence.
Under the terms of the agreement, NewLink Genetics will receive a payment of $20 million in connection with the achievement of the milestone. The milestone pertains to the initiation of a key clinical trial for the vaccine.
Insomnia drug sales will fall rapidly from $2.1 billion in 2013 to $1.4 billion by 2016, before steadily recovering to $1.8 billion by 2023, driven by the launch of two products, Merck & Co.’s Belsomra and Eisai’s E-2006, and an increase in the prevalent cases of insomnia, says research and consulting firm GlobalData.
Merck has announced that the company and Bristol-Myers Squibb have agreed to transfer full responsibility for the promotion of Erbitux® (cetuximab) to Merck in Japan as of May 1, 2015
Merck's fourth-quarter profit skyrocketed to $7.32 billion, skewed by an $11.2 billion gain from selling its consumer health business to Germany's Bayer AG.
Merck has announced that BELSOMRA (suvorexant) is now available at pharmacies in the United States for the treatment of insomnia in adults who have difficulty falling asleep and/or staying asleep. BELSOMRA is the only orexin receptor antagonist approved for the treatment of insomnia in the United States.
Merck announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending approval of the investigational antibiotic SIVEXTRO® for the treatment of acute bacterial skin and skin structure infections in adults.
Moderna Therapeutics has announced a license and collaboration agreement with Merck for the discovery and development of vaccines and passive immunity treatments against viral diseases using modified messenger RNA (mRNA).
Merck is ratcheting up its race with rival Bristol-Myers Squibb Co. for leadership in one of today's hottest research areas, immuno-oncology, which harnesses the immune system to fight cancer.
Merck and Eli Lilly announced today an oncology clinical trial collaboration to evaluate the safety, tolerability and efficacy of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Lilly compounds in multiple clinical trials.
Merck today will report on the ongoing execution of its multi-year, strategic initiative to sharpen its commercial and research and development (R&D) focus, redesign its operating model and reduce its cost base. In October 2013, Merck launched its global initiative to transform the company into a more competitive and innovative company and to build a platform for sustained future growth.
After an expert meeting this week, WHO said there is now enough information to conclude that the two most advanced Ebola vaccines — one made by GlaxoSmithKline and the other licensed by Merck and NewLink — have "an acceptable safety profile."
EnWave Corporation has signed a non-exclusive Research and Development License Agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary to enable testing and advancement of the Company's Radiant Energy Vacuum ("REV™") dehydration technology in the pharmaceutical industry.
The Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services has awarded NewLink Genetics' subsidiary, BioProtection Systems, as the prime contractor in a $30M contract to support the manufacturing and development activities of its investigational Ebola vaccine candidate.
Merck has acquired, through a subsidiary, OncoEthix, a Swiss-based privately held biotechnology company specializing in oncology drug development. Through the acquisition, Merck has gained an investigational, novel oral BET inhibitor, OTX015, which is currently in Phase 1b studies for the treatment of hematological malignancies and advanced solid tumors.
The FDA has approved Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for the prevention of certain diseases caused by nine types of Human Papillomavirus (HPV). Covering nine HPV types, five more HPV types than Gardasil, Gardasil 9 has the potential to prevent approximately 90 percent of cervical, vulvar, vaginal and anal cancers.
- Page 1